<DOC>
	<DOCNO>NCT00148707</DOCNO>
	<brief_summary>The purpose study collect information effect ( good bad ) CT-2103 ( Xyotax ) breast cancer well side effect drug may cause .</brief_summary>
	<brief_title>Study Xyotax ( CT-2103 ) Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>- Patients give CT-2103 intravenously every 3 week . One week first dose CT-2103 physical exam , blood work assessment side effect perform . - Prior injection CT-2103 , physical exam , blood work assessment side effect perform ( every 3 week ) . - Every 6 week patient 's cancer re-evaluated either CT scan MRI determine whether treatment work . - Additional blood work perform per week first two dos CT-2103 . - The participation study last least 2 cycle ( 6 week ) , however patient may remain study long disease progression , able tolerate study drug without severe side effect .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis invasive breast cancer , Stage IV disease Age great 18 year At least one measurable target lesion define RECIST previously treat local therapy HER2negative breast cancer Up one prior chemotherapy advance metastatic disease ECOG performance status 01 Life expectancy &gt; 12 week Adequate liver bone marrow function : AST &lt; 2.5 x ULN ; Bilirubin &lt; 1.5 x ULN ; ANC &gt; 1,500/ul ; platelet count &gt; 100,000/ul ; normal PT PTT At least 2 week since prior radiation recover treatmentrelated toxicity Prior taxanes treatment metastatic disease Pregnant breastfeed woman HER2positive breast cancer More 1 prior chemotherapy regimen metastatic disease Untreated brain metastasis Concurrent radiotherapy investigational drug Prior bone marrow stem cell transplant History malignancy within last 5 year , include curativelytreated carcinoma situ cervix nonmelanoma skin cancer Uncontrolled infection Active bleeding , history bleed require transfusion Active cardiac disease Serious medical psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>HER2-negative Breast Cancer</keyword>
	<keyword>CT-2103</keyword>
	<keyword>Xyotax</keyword>
</DOC>